By Denny Jacob
Actuate Therapeutics said its treatment for Ewing sarcoma was granted rare pediatric-disease designation from the Food and Drug Administration.
Chief Executive Daniel Schmitt said early clinical data from the ongoing Phase 1/2 trial of elraglusib shows promising anti-tumor activity with objective tumor responses.
Ewing sarcoma is a highly metastatic form of sarcoma that originates in bone with a peak incidence at the age of 15, the clinical-stage biopharmaceutical company said.
The FDA's pediatric-disease designation is granted for serious or life-threatening ailments that affect fewer than 200,000 people in the U.S., and which the serious or life-threatening manifestations primarily affect individuals less than 18 years old.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
November 12, 2024 08:34 ET (13:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.